Payment overview · 2025
General Payments
$897.78
52 reported records · 16 companies
Healthcare provider profile · identity verified
Edward Burke, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FREDERICKTOWN, MO · NPI 1306885157
Verified facts
What the public records show
CMS Open Payments records show Edward Burke, M.D. received $897.78 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Farxiga, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 639 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 436 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abilify Maintena by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 639 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.49 | 22.1% | 18 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $138.58 | 15.4% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $87.49 | 9.8% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $82.82 | 9.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.73 | 7.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.56 | 7.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.96 | 6.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.10 | 4.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.38 | 3.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.85 | 2.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.88 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.73 | 2.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.13 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.09 | 1.9% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $16.99 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.00 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $810.29 | 51 |
| Education | $87.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $185.50 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.48 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.73 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $70.73 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.01 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.96 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $27.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 239 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
639 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
239 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
436 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
639 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 34 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1052 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1045 | 128 |
| Gabapentin | Gabapentin | 974 | 124 |
| Furosemide | Furosemide | 898 | 94 |
| Lisinopril | Lisinopril | 745 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 693 | 93 |
| Potassium Chloride | Potassium Chloride | 671 | 73 |
| Famotidine | Famotidine | 661 | 72 |
| Eliquis | Apixaban | 639 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 537 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 483 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 456 | 46 |
| Jardiance | Empagliflozin | 436 | 28 |
| Metformin Hcl | Metformin Hcl | 434 | 57 |
| Trazodone Hcl | Trazodone Hcl | 430 | 66 |
| Montelukast Sodium | Montelukast Sodium | 383 | 46 |
| Sertraline Hcl | Sertraline Hcl | 347 | 49 |
| Buspirone Hcl | Buspirone Hcl | 345 | 47 |
| Omeprazole | Omeprazole | 311 | 47 |
| Xarelto | Rivaroxaban | 304 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 299 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 43 |
| Losartan Potassium | Losartan Potassium | 288 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 30 |
| Tramadol Hcl | Tramadol Hcl | 274 | 40 |
| Myrbetriq | Mirabegron | 263 | 15 |
| Divalproex Sodium | Divalproex Sodium | 258 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 246 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 239 | 36 |
| Carvedilol | Carvedilol | 235 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 227 | 32 |
| Mirtazapine | Mirtazapine | 226 | 37 |
| Spironolactone | Spironolactone | 218 | 29 |
| Clonazepam | Clonazepam | 212 | 27 |
| Donepezil Hcl | Donepezil Hcl | 209 | 24 |
| Baclofen | Baclofen | 207 | 20 |
| Pregabalin | Pregabalin | 206 | 30 |
| Prednisone | Prednisone | 203 | 48 |
| Benztropine Mesylate | Benztropine Mesylate | 195 | 17 |
| Alprazolam | Alprazolam | 187 | 25 |
| Simvastatin | Simvastatin | 186 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 61 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 181 | 18 |
| Allopurinol | Allopurinol | 173 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 169 | 28 |
| Lorazepam | Lorazepam | 168 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 20 |
| Levetiracetam | Levetiracetam | 166 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 161 | 14 |
| Olanzapine | Olanzapine | 161 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 159 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 158 | 11 |
| Gemtesa | Vibegron | 142 | 11 |
| Memantine Hcl | Memantine Hcl | 141 | 21 |
| Topiramate | Topiramate | 140 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 139 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 138 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 22 |
| Aripiprazole | Aripiprazole | 136 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 16 |
| Haloperidol | Haloperidol | 130 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 17 |
| Meloxicam | Meloxicam | 120 | 18 |
| Propranolol Hcl | Propranolol Hcl | 120 | 12 |
| Vascepa | Icosapent Ethyl | 108 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 28 |
| Prazosin Hcl | Prazosin Hcl | 107 | 13 |
| Latanoprost | Latanoprost | 106 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 104 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 104 | 60 |
| Ozempic | Semaglutide | 100 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 14 |
| Alendronate Sodium | Alendronate Sodium | 99 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 98 | 23 |
| Januvia | Sitagliptin Phosphate | 98 | suppressed |
| Carbamazepine | Carbamazepine | 96 | suppressed |
| Ibuprofen | Ibuprofen | 96 | 29 |
| Fenofibrate | Fenofibrate | 95 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 92 | 12 |
| Risperidone | Risperidone | 92 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 90 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 89 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 12 |
| Ondansetron Odt | Ondansetron | 86 | 35 |
| Nystatin | Nystatin | 85 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 46 |
| Trintellix | Vortioxetine Hydrobromide | 83 | suppressed |
| Azithromycin | Azithromycin | 82 | 60 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | suppressed |
| Celecoxib | Celecoxib | 81 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 79 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 49 |
| Lovastatin | Lovastatin | 78 | suppressed |
| Glipizide | Glipizide | 75 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 74 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 74 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 12 |
| Sucralfate | Sucralfate | 71 | suppressed |
| Linzess | Linaclotide | 70 | 12 |
| Invega Sustenna | Paliperidone Palmitate | 69 | 12 |
| Finasteride | Finasteride | 68 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | suppressed |
| Digoxin | Digoxin | 66 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 64 | suppressed |
| Methocarbamol | Methocarbamol | 63 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | suppressed |
| Atenolol | Atenolol | 62 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | suppressed |
| Levofloxacin | Levofloxacin | 60 | 45 |
| Bupropion Xl | Bupropion Hcl | 59 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | 25 |
| Trulicity | Dulaglutide | 55 | 11 |
| Colestipol Hcl | Colestipol Hcl | 54 | suppressed |
| Diazepam | Diazepam | 54 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 53 | suppressed |
| Glimepiride | Glimepiride | 52 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 52 | suppressed |
| Vraylar | Cariprazine Hcl | 51 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 50 | 15 |
| Calcitriol | Calcitriol | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Acyclovir | Acyclovir | 48 | 11 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Pentoxifylline | Pentoxifylline | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | 19 |
| Levemir Flexpen | Insulin Detemir | 46 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 23 |
| Folic Acid | Folic Acid | 45 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 45 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 43 | 12 |
| Cilostazol | Cilostazol | 41 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 41 | suppressed |
| Irbesartan | Irbesartan | 41 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 39 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 33 |
| Primidone | Primidone | 37 | suppressed |
| Austedo | Deutetrabenazine | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 13 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 34 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Nyamyc | Nystatin | 34 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Abilify Maintena | Aripiprazole | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 19 |
| Naproxen | Naproxen | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Fetzima | Levomilnacipran Hcl | 26 | suppressed |
| Lacosamide | Lacosamide | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Austedo Xr | Deutetrabenazine | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 17 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Loxapine | Loxapine Succinate | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 22 |
| Ziprasidone Hcl | Ziprasidone Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 12 |
| Perphenazine | Perphenazine | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Paliperidone Er | Paliperidone | 21 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Olanzapine Odt | Olanzapine | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Constulose | Lactulose | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Galantamine Er | Galantamine Hbr | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Brinzolamide | Brinzolamide | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Clobazam | Clobazam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $897.78 · 52 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, BREZTRI, CAPLYTA, COBENFY, Cologuard Collection Kit, DAYBUE, FARXIGA, INGREZZA, LYBALVI, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZAVZPRET | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error